Ganoci, L.; Palić, J.; Trkulja, V.; Starčević, K.; Šimičević, L.; Božina, N.; Lovrić-Benčić, M.; Poljaković, Z.; Božina, T.
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes 2024, 15, 607.
https://doi.org/10.3390/genes15050607
AMA Style
Ganoci L, Palić J, Trkulja V, Starčević K, Šimičević L, Božina N, Lovrić-Benčić M, Poljaković Z, Božina T.
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes. 2024; 15(5):607.
https://doi.org/10.3390/genes15050607
Chicago/Turabian Style
Ganoci, Lana, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Nada Božina, Martina Lovrić-Benčić, Zdravka Poljaković, and Tamara Božina.
2024. "Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?" Genes 15, no. 5: 607.
https://doi.org/10.3390/genes15050607
APA Style
Ganoci, L., Palić, J., Trkulja, V., Starčević, K., Šimičević, L., Božina, N., Lovrić-Benčić, M., Poljaković, Z., & Božina, T.
(2024). Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients? Genes, 15(5), 607.
https://doi.org/10.3390/genes15050607
